François Moreau is the Chief Scientific Officer at Tamrisa Innovation, the R&D business unit of Tamrisa, a company focused on the research, development, and commercialization of anti-infectives. He has 25 years of experience in drug discovery, beginning at Pfizer, where he worked in enzymology, small molecule screening, and biophysics for allergy and respiratory disease programs.
For most of his professional career, Francois has been devoted to drug discovery of anti-infectives at Mutabilis (now Tamrisa Innovation), where he first investigated various strategies for inhibiting virulence in Gram-positive and Gram-negative bacteria, leading to several patents and publications. He also contributed to the development of a new class of antibacterials, the FabI inhibitors, and a new class of antiretrovirals, the allosteric inhibitors of HIV integrase.
Francois’s current focus is on the discovery and development of an exciting novel class of antibacterials targeting the penicillin-binding proteins (PBPs), with the potential to reset the clock of antibacterial resistance to beta-lactams: the diazabicyclooctanes (DBOs). Tamrisa Innovation’s R&D programs are or have been supported by IMI (ENABLE), CARB-X, the REPAIR Impact Fund, and Roche.
François earned a PhD in Bioorganic Chemistry from Sorbonne University, Paris, in 1997, following training as an engineer in physics and chemistry at ESPCI Paris. He is the co-author of 24 scientific publications and the co-inventor of 11 patents.